| Ian A Meyer, DO | |
|
8251 Pine Road, Suite 212, Cincinnati, OH 45236 | |
| (513) 841-0222 | |
| (513) 841-0638 |
| Full Name | Ian A Meyer |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 8251 Pine Road, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083836043 | NPI | - | NPPES |
| 2605694 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 34008568 (Ohio) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 34.008568 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc-liberty Dialysis-kenwood | Kenwood, OH | Dialysis facility |
| Fmc - Liberty Norwood | Norwood, OH | Dialysis facility |
| Bethesda North | Cincinnati, OH | Hospital |
| Christ Hospital | Cincinnati, OH | Hospital |
| The Jewish Hospital-mercy Health | Cincinnati, OH | Hospital |
| Mercy Health - West Hospital | Cincinnati, OH | Hospital |
| Good Samaritan Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mt. Auburn Nephrology Inc. | 6901894229 | 12 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
A dynamic slogan designed to grab attention "Be bold. Be daring. Be caring and support decriminalisation," has been used in an attempt by the Royal College of Nursing in the UK, to call on the government to decriminalise prostitution in order to protect the health of vulnerable women and men who feel unable to access NHS and social services.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
By adding features to commonly used chemical-engineering software packages, researchers at the University of Arkansas, the University of Akron and Chemstations Inc. have developed adaptive technology that allows blind or visually impaired students and working professionals to perform the essential functions of chemical-engineering process design.
› Verified 9 days ago
| Entity Name | Mt. Auburn Nephrology Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578563284 PECOS PAC ID: 6901894229 Enrollment ID: O20040505000446 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
A dynamic slogan designed to grab attention "Be bold. Be daring. Be caring and support decriminalisation," has been used in an attempt by the Royal College of Nursing in the UK, to call on the government to decriminalise prostitution in order to protect the health of vulnerable women and men who feel unable to access NHS and social services.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
By adding features to commonly used chemical-engineering software packages, researchers at the University of Arkansas, the University of Akron and Chemstations Inc. have developed adaptive technology that allows blind or visually impaired students and working professionals to perform the essential functions of chemical-engineering process design.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ian A Meyer, DO 8251 Pine Road, Suite 212, Cincinnati, OH 45236 Ph: (513) 841-0222 | Ian A Meyer, DO 8251 Pine Road, Suite 212, Cincinnati, OH 45236 Ph: (513) 841-0222 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
A dynamic slogan designed to grab attention "Be bold. Be daring. Be caring and support decriminalisation," has been used in an attempt by the Royal College of Nursing in the UK, to call on the government to decriminalise prostitution in order to protect the health of vulnerable women and men who feel unable to access NHS and social services.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
By adding features to commonly used chemical-engineering software packages, researchers at the University of Arkansas, the University of Akron and Chemstations Inc. have developed adaptive technology that allows blind or visually impaired students and working professionals to perform the essential functions of chemical-engineering process design.
› Verified 9 days ago
Moises Arturo Huaman Joo, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman Street, Cincinnati, OH 45219 Phone: 513-584-6977 Fax: 513-584-4281 | |
Dr. Kiranmayee Lanka, M.D., M.P.H Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2123 Auburn Ave, Suite 401, Cincinnati, OH 45219 Phone: 513-241-5489 Fax: 513-241-5490 | |
Dr. Saurabh Chandra, MD Nephrology Medicare: Medicare Enrolled Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-558-1000 | |
Gretchen Suarez, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 10500 Montgomery Rd, Cincinnati, OH 45242 Phone: 513-865-2246 Fax: 513-865-5596 | |
Dr. Andrew Michael Espinal, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 4777 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-686-3000 | |
Sorina M Macavei, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 463 Ohio Pike, Suite 300, Cincinnati, OH 45255 Phone: 513-528-5600 Fax: 513-528-9716 | |
Helen K Koselka, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 3219 Clifton Ave, Suite 100, Cincinnati, OH 45220 Phone: 513-528-5600 Fax: 513-528-9716 |